Table 4.

Performance of risk prediction models for hepatocellular carcinoma development at 5 years

	CU-HCC score	GAG-HCC score	Pa	REACH-B score	Pa	PAGE-B score	Pa	Modified PAGE-B score	Pa	aMAP score	Pa
Original components	Age, albumin, bilirubin, HBV DNA, cirrhosis	Age, sex, BCP mutation, HBV DNA levels, cirrhosis		Age, sex, ALT, HBV DNA, HBeAg		Age, sex, platelet counts		Age, sex, platelet count, albumin		Age, sex, bilirubin, albumin, platelet count
Components used in this study	Age, albumin, bilirubin, cirrhosis	Age, sex, cirrhosis		Age, sex, ALT,		Age, sex, platelet counts		Age, sex, platelet count, albumin		Age, sex, bilirubin, albumin, platelet count
Overall (n = 1,200)
AUROC (95% CI)	0.82 (0.70–0.93)	0.81 (0.70–0.93)	0.60	0.64 (0.52–0.75)	0.03	0.62 (0.49–0.75)	0.01	0.72 (0.61–0.82)	0.08	0.73 (0.63–0.84)	0.03
Spontaneous (n = 984)
AUROC (95% CI)	0.79 (0.62–0.96)	0.82 (0.65–0.98)	0.92	0.66 (0.49–0.83)	0.20	0.65 (0.49–0.81)	0.26	0.77 (0.64–0.90)	0.81	0.71 (0.59–0.83)	0.31
AVT induced (n = 216)
AUROC (95% CI)	0.81 (0.632–0.98)	0.74 (0.58–0.90)	0.19	0.70 (0.56–0.84)	0.48	0.53 (0.31–0.76)	0.007	0.67 (0.51–0.82)	0.06	0.73 (0.53–0.93)	0.08

^aP value, compared with CU-HCC score. For CU-HCC score, 0 point was given for HBV DNA score. For GAG-HCC score, 0 point was given for HBV DNA and BCP mutation. For REACH-B score, 0 point was given for HBV DNA and HBeAg.

aMAP, age-male-ALBI-platelets; AUROC, area under the receiver operating characteristic curve; ALT, alanine aminotransferase; AVT, antiviral therapy; BCP, basal core promoter; CI, confidence interval; CU-HCC, Chinese University-HCC; GAG-HCC, guide with age, gender, HBV DNA, core promoter mutations and cirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; PAGE-B, platelets, age, gender hepatitis B; REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B.